J&J seeks dismissal of US case claiming kickbacks to Omnicare
This article was originally published in Scrip
Executive Summary
Johnson & Johnson is aggressively fighting claims in a whistleblower lawsuit, joined by the US Department of Justice and several states, which charges that J&J paid tens of millions of dollars in kickbacks between 1999 and 2004 to induce Omnicare, a provider of pharmacy services, to boost use of J&J medicines such as the antipsychotic Risperdal (risperidone) to its nursing home clients. J&J argues that the alleged kickbacks were standard, legal contracting arrangements pertaining to increased rebates for obtaining market share, and are allowable under federal law.